Open AccessSPECT/CT versus planar imaging to determine treatment strategy for non-small-cell lung cancer: a cost–effectiveness analysis
Author(s) -
Jonathan Romsa,
Ryan J Imhoff,
Swetha R Palli,
Richard Inculet,
Sanjay Mehta
Publication year - 2022
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer-2021-0139
Subject(s) - medicine , scintigraphy , lung cancer , radiology , lung , nuclear medicine , surgery , lung volumes , pneumonectomy , quality adjusted life year , predictive value of tests , clinical practice , clinical decision making , medline , respiratory disease , volume (thermodynamics) , retrospective cohort study , surgical procedures , lung volume reduction surgery
Aim: SPECT/CT has been found to improve predicted postoperative forced expiratory volume in one second (ppoFEV 1 ) assessments in patients with non-small-cell lung cancer (NSCLC). Methods: An economic simulation was developed comparing the cost–effectiveness of SPECT/CT versus planar scintigraphy for a US payer. Clinical outcomes and cost data were obtained through review of the published literature. Results: SPECT/CT increased the accuracy ppoFEV 1 assessment, changing the therapeutic decision for 1.3% of nonsurgical patients to a surgical option, while 3.3% of surgical patients shifted to more aggressive procedures. SPECT/CT led to an expected cost of $4694 per life year gained, well below typical thresholds. Conclusion: SPECT/CT resulted in substantially improved health outcomes and was found to be highly cost-effective.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom